
Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, discuss emerging agents in the pipeline and the future treatment landscape for CLL.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, comment on the role of pharmacists in clinical practice for managing patients with CLL.

Key opinion leaders in hematology-oncology share recommendations on switching from first-generation BTK inhibitors to next-generation BTK inhibitors for the management of patients with CLL.

Dr Ryan Jacobs, MD, leads a review of the phase 3 SEQUOIA trial presented at ASH 2021 evaluating the use of zanubrutinib for previously untreated CLL and discusses the management of adverse events with BTK inhibitors.

Ryan Jacobs, MD, and Bhavesh Shah, RPh, BCOP, provide insight on considerations when choosing a BTK inhibitor for initial treatment of chronic lymphocytic leukemia.

Experts in hematology/oncology discuss goals of therapy and optimal treatment selection for patients with chronic lymphocytic leukemia.

Dr Ryan Jacobs evaluates the use of chemotherapy options for first-line treatment of CLL.

Bhavesh Shah, RPh, BCOP, and Ryan Jacobs, MD, share considerations for approaching an individualized treatment regimen for patients with CLL.

The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.

What pharmacists need to know about BTK inhibitor drug activity, dosing, and interactions in Waldenström macroglobulinemia.

An overview of BTK inhibitors available as first-line therapy for Waldenström macroglobulinemia, and variables that impact treatment selection and the switching of agents throughout the course of therapy.

Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.

The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.

What pharmacists need to know about the adoption of novel targeted therapies for Waldenstrom macroglobulinemia into regular clinical practice.

The criteria used by hematologists and oncologists to guide decisions to initiate therapy for Waldenstrom macroglobulinemia vs monitor patients with active surveillance.

An overview of the types of biomarkers that play a role in the manifestation of Waldenstrom macroglobulinemia.

The characteristics of Waldenstrom macroglobulinemia that distinguish the disease from other types of lymphomas.

Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.

Moving beyond BTK inhibition in marginal zone lymphoma, expert panelists review other therapies and drug classes with indications in this setting.

Panelists look at the class effects of BTK inhibitors and share optimal strategies to select therapy and manage toxicities.

Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.

A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.

Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.

Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.

Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.

The US health care system expects 2020 to be a year of major cost savings, in part because of the projected significant traction from 3 major biosimilars for rituximab (Rituxan), bevacizumab (Avastin), and trastuzumab (Herceptin), which accounted for a total of $19.4 billion in sales in 2018.

Published: February 24th 2022 | Updated:

Published: March 10th 2022 | Updated:

Published: March 10th 2022 | Updated:

Published: February 24th 2022 | Updated:

Published: March 10th 2022 | Updated:

Published: March 17th 2022 | Updated: